Home > News > AMSBIO Announces the Extensive CAR-T Cell Range for Research & Immunotherapy
Industry Updates New Products Supplier News Upcoming Events business web

AMSBIO Announces the Extensive CAR-T Cell Range for Research & Immunotherapy

Hits:191   Date: 7/10/2019
Extensive CAR-T Cell Range for Research & Immunotherapy

AMSBIO announce new, best-in-class CAR-T cells, engineered CAR-T target cells, PBMC, cell media and activation beads in response to the rapid growth in research on the therapeutic uses of CAR-T cells.

All CAR-T cell products from AMSBIO are T cells produced from either a group of donors or from individual donor transduced with CAR (Chimeric antigen receptor) - lentivirus.

These CAR-T cells can target different tumor antigens such CD19, CD133, Her-2, EGFR, VEGFR-2 or mesothelin that are highly over-expressed in tumors. These CAR-T cells can express inducible caspase-9 or other suicide gene to induce CAR-T cell killing for increased safety in case this construct in future will be proposed to use in clinical trials. All CAR-T cell products from AMSBIO can be validated for transduction efficiency, cell killing activity and Real time cytotoxicity activity. All CAR-T cells from AMSBIO have negative mock controls: lentivirus-transduced CAR-T cells, no ScFv-transduced CAR-T cells and non-transduced T cells.

In addition to these off-the-shelf CAR-T cell products, AMSBIO offers a growing list of engineered cell lines including CAR-T/NK cells and target cells (GFP-Raji cells) to support custom development in applications including animal studies.

PBMC (Peripheral Blood Mononuclear Cells) from AMSBIO are isolated from blood samples using standard Ficoll-Paque and density gradient centrifugation. These PMBC cells can be used for isolation of T cells (used to generate CAR-T cells) and other cell types.

AMSBIO's new CAR T-cell Expansion Medium is specifically optimized for expansion of CAR T-cells, providing 100-fold greater expansion than normal media. CD28 / CD3 cell activation / expansion beads have been introduced to enable researchers to activate and expand human T cells: CD4+, CD8+ T cells, antigen specific T cells or polyclonal T cells.

For further information please on the extensive CAR-T cell product range please visit http://www.amsbio.com/car-t-cell-research.aspx or contact AMSBIO on 44-1235-828200/+1-617-945-5033 /info@amsbio.com. 

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. 

For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology. 

Worldwide HQ 

AMS Biotechnology (AMSBIO)
184 Milton Park
Abingdon
Oxon OX14 4SE
UK
Tel: +44-1235-828200
Fax: +44-1235-820482
Email: info@amsbio.com 
Web www.amsbio.com
 
North American HQ
 
AMSBIO LLC
1035 Cambridge Street
Cambridge
MA 02141
USA
Tel: +1.617.945.5033 
Tel: +1.800.987.0985 (toll free)
Email: info@amsbio.com 
Web www.amsbio.com
AMSBIO
Tel:+44 (0) 1235 828 200
E-mail:info@amsbio.com
advertisement